Medical Device

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that it has closed a non-brokered private placement financing of 10 million units at a price of $0.15 per unit (a "Unit") for gross proceeds of $1,500,000 (the "Offering").

Each Unit consists of one common share of LevelJump and one common share purchase warrant ("Warrant"). Each Warrant entitles the holder to acquire one additional common share of LevelJump at an exercise price of $0.20 until March 31, 2024.

The net proceeds from the financing will be used towards acquisitions and for general working capital purposes.

The securities issued under the Offering have a hold period of four months and one day from the closing date in accordance with applicable securities laws.

"We are really pleased with the market response to our offering, and the support of our strategic investors who believe in the vision of the Company," said Mitch Geisler CEO. "We have now strengthened our balance sheet. Given that our CTS subsidiary generates positive cash flow from its current operations we can designate this new capital towards growing the Company."

About Leveljump Healthcare

LevelJump Healthcare Corp., (TSXV: JUMP) is building a national medical diagnostic imaging company and brand, primarily by providing teleradiology (remote radiology) services to its client hospitals and imaging centers. Additionally, JUMP plans to expand through the acquisition of independent healthcare facilities focused on diagnostic imaging as well as acquiring new disruptive imaging technologies.

ON BEHALF OF THE BOARD OF DIRECTORS OF
LevelJump Healthcare Corp.

Mitchell Geisler, Chief Executive Officer
info@leveljumphealthcare.com
(833) 840-2020

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83719

News Provided by Newsfile via QuoteMedia

BioHarvest Sciences Inc. Announces Live Quarterly Shareholder Update Event July 7, 2022, at 2:00 PM ET

BioHarvest Sciences Inc. Announces Live Quarterly Shareholder Update Event July 7, 2022, at 2:00 PM ET

 BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or "the Company") invites its shareholders and the general public to join a Live Video Conference ("Webinar") on Thursday, July 7, 2022, at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time).

BioHarvest Sciences CEO Ilan Sobel will host the event, which will include coverage of Q2 sales results and a detailed progress update on the 2022 Growth Priorities, with specific focus on the VINIA scale-up progress in the USA and on the Company's Cannabis market entry strategy into North America.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Nanalysis Announces Results of AGM and Appointment of New Director

Nanalysis Scientific Corp. ("the Company", ("the Company", TSXV: NSCI OTCQX: NSCIF FRA: 1N1 ) a leader in portable NMR machines and MRI technology for healthcare and industrial applications, is pleased to report that all proposed resolutions were approved at the Company's Annual General and Special Meeting of shareholders held on June 22, 2022 (the "Meeting"). The number of directors was set at 7 and all director nominees, as listed in the Management Information Circular dated May 20, 2022 (the "Information Circular"), were elected as directors of the Company at the Meeting to serve for a one-year term and hold office until the next annual meeting of shareholders. According to the proxy votes received from shareholders, the results were as follows:

Nanalysis Scientific Corp. (CNW Group/Nanalysis Scientific Corp.)

Nominees:


% For


% Withheld






Sean Krakiwsky


96.566 %


3.434 %

Martin Burian


95.592 %


4.408 %

Werner Gartner


99.852 %


0.148 %

Michal Okoniewski


99.852 %


0.148 %

Guido Cloetens


95.628 %


4.372 %

Rene Lenggenhager


99.852 %


0.148 %

Kham Lin


99.609 %


0.391 %

Shareholders voted 99.85% in favor of setting the number of directors at seven, 99.6% in favor of appointing Ernst & Young LLP, as auditor of the Company for the ensuing year and to authorize the Directors of the Company to fix the auditor's remuneration and 98.1% in favor for the approval of an amended stock option plan of the Company.

Corporate Update

The Company is pleased to welcome Kham Lin to Nanalysis's Board of Directors with immediate effect following shareholder approval at the Meeting.

Mr. Lin is currently a Managing Director at Nanalysis and was formerly the President and Chief Executive Officer of KPrime Technologies before the Company's acquisition by Nanalysis.  Over twenty plus years, Mr. Lin built KPrime, into a manufacturing representative business for global companies like Agilent Technologies, Metrohm USA , Sartorius LPS Division, and Leidos.  KPrime has a portfolio of sales and services in scientific detection and measuring equipment, financing, and asset management for chemical and security industries.  Mr. Lin resides and works in Calgary, Alberta, Canada but also splits time in Phoenix, Arizona at KPrime Headquarters.

About Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA:1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI', OTC and the Frankfurt exchange under the ticker symbol '1N1'. The company's business is what we term "MRI and NMR for industry". The company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The company has followed-up that initial offering with new products and continues to have a strong innovation pipeline. Nanalysis recently announced that it has begun selling a 100MHz device in 2020. The Company's new device will be the most powerful and most advanced compact NMR device ever brought to market.

Nanalysis devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company continues to exploit new global market opportunities independently and with partners.

With the recent acquisition of K'Prime, the company maintains a North American sales and service company of over 40 individuals who cover scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems for security applications.

Additionally, the Company has a 43% ownership in Quad Systems AG ("Quad Systems"), with an option to purchase the remaining shares.  Quad Systems is a Zurich-based Nuclear Magnetic Resonance (NMR) company focused on high-field NMR for pharmaceutical and other vertical markets.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/nanalysis-announces-results-of-agm-and-appointment-of-new-director-301574013.html

SOURCE Nanalysis Scientific Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2022/23/c9517.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Applied UV Continues Cannabis Market Expansion

Applied UV Continues Cannabis Market Expansion

Tru Infusion Places Significant Order

Largest Indoor Cannabis Cultivator in Arizona

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Greenlane Renewables Announces Results From 2022 Annual General Meeting of Shareholders

Greenlane Renewables Announces Results From 2022 Annual General Meeting of Shareholders

~All nominated directors and proposed resolutions approved by shareholders~

 Greenlane Renewables Inc. ("Greenlane") (TSX: GRN) (FSE: 52G) is pleased to announce the results from its 2022 Annual General Meeting of Shareholders held on June 22, 2022 (the "Meeting"). Shareholders approved all matters submitted to them for approval at the annual general meeting. The results of the voting are set forth below:

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Applied UV Receives Substantial Order from European Distributor

Applied UV Receives Substantial Order from European Distributor

Cellarius is One of Europe's Fastest Growing Companies

Expanding Airocide's Global Winery Market share

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Playground Ventures Announces Appointment of CFO

Playground Ventures Announces Appointment of CFO

Playground Ventures Inc. (CSE: PLAY) (the "Company" or "Playground") announces that Nidhi Kumra has resigned as the Company's Chief Financial Officer, effectively May 31, 2022. The Board of Directors and management would like to thank Ms. Kumra for her contributions to the Company and wish her every success in her future endeavors.

The Company is also pleased to announce that Kaylee Whitcroft, the Company's Operations Accounting Manager, has been appointed the Chief Financial Officer of the Company.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×